Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and its wholly owned subsidiary Pet2DAO, Inc. have announced that registration is now open for BIO REBOOT, an initiative powered by the company’s PDAOAI artificial intelligence drug discovery platform. The program invites scientists, AI developers and biotech founders to bring their research questions, technical expertise and drug discovery ideas to the PDAOAI community. Selected projects may be considered for startup funding and support from Oncotelic covering validation, formulation, regulatory planning and clinical development, according to the announcement.
The news matters because it signals a push to democratize access to AI-driven drug discovery and could accelerate the translation of promising ideas into viable therapies by providing both funding and development expertise. By opening participation to a broad community, Oncotelic aims to foster collaborative innovation in oncology and immunotherapy, areas where the company focuses on cancers with substantial unmet needs and rare pediatric indications.
In addition to BIO REBOOT, Oncotelic announced two PDAOAI keynote presentations at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for Oct. 7-9, 2026, in Burlingame, California. Saran Saund, Chief Business Officer, will present a hepatocellular carcinoma case study illustrating how Partitioned Literature Aggregation generated a candidate four-gene signature. Scott Myers, Product Manager, will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations will highlight the platform’s capabilities and its potential to streamline target identification and validation.
For investors and industry observers, the announcements underscore Oncotelic’s commitment to advancing its PDAOAI platform as a core component of its drug discovery and development efforts. The company’s focus on rare pediatric indications and high-unmet-need cancers aligns with growing interest in precision medicine and AI-driven approaches. The full press release is available at https://ibn.fm/dxB7y, and the latest updates on OTLC can be found in the company’s newsroom at https://ibn.fm/OTLC.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences and life sciences. BioMedWire is part of the Dynamic Brand Portfolio within IBN, which provides wire solutions through InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. The original release includes disclaimers available at https://www.BioMedWire.com/Disclaimer.
